Myriad Genetics, Inc.

NasdaqGS:MYGN Stock Report

Market Cap: US$428.3m

Myriad Genetics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Sam Raha

Chief executive officer

US$4.4m

Total compensation

CEO salary percentage17.09%
CEO tenure1yr
CEO ownership0.2%
Management average tenure3.1yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Myriad Genetics: SOTP Suggests The Company Is Undervalued

Mar 31

Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding

Feb 13
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Feb 04
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop

May 09
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop
User avatar

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 16
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Feb 26
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Myriad Genetics: Navigating Through A Setback

Jan 16

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Jan 08
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Sep 20
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

CEO Compensation Analysis

How has Sam Raha's remuneration changed compared to Myriad Genetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$366m

Sep 30 2025n/an/a

-US$400m

Jun 30 2025n/an/a

-US$395m

Mar 31 2025n/an/a

-US$101m

Dec 31 2024US$4mUS$750k

-US$127m

Sep 30 2024n/an/a

-US$116m

Jun 30 2024n/an/a

-US$155m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$5mUS$14k

-US$263m

Compensation vs Market: Sam's total compensation ($USD4.39M) is above average for companies of similar size in the US market ($USD2.45M).

Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.

CEO

Sam Raha (52 yo)

1yr
Tenure
US$4,389,327
Compensation

Mr. Samraat S. Raha, also known as Sam, served as Chief Operating Officer at Myriad Genetics, Inc. since December 11, 2023 until April 30, 2025 and serves as its President, Chief Executive Officer and Dire...

Leadership Team

NamePositionTenureCompensationOwnership
Samraat Raha
President1yrUS$4.39m0.17%
$ 741.8k
Mark Verratti
Chief Operating Officer1yrUS$3.71m0.67%
$ 2.9m
Dale Muzzey
Chief Scientific Officer4.3yrsUS$3.01m0.35%
$ 1.5m
Paul Diaz
Consultant & Director1yrUS$13.63m0.66%
$ 2.8m
Benjamin Wheeler
CFO & Principal Accounting Officerless than a yearno data0.32%
$ 1.4m
Matthew Scalo
Senior Vice President of Investor Relationsno datano datano data
Jennifer Fox
Chief Legal Officer1.6yrsno data0.028%
$ 119.4k
Shereen Solaiman
Chief People Officer3.1yrsno data0.037%
$ 159.7k
Patrick Burke
Executive Vice President of Innovation & Strategic Partnerships4.9yrsno datano data
Thomas P. Slavin
Chief Medical Officer6.1yrsno datano data
David Hammer
Senior Vice President of Revenue Cycle Management5.2yrsno datano data
Chris Williamson
Senior Vice President of Information Systems & Security5.2yrsno datano data
3.1yrs
Average Tenure
52yo
Average Age

Experienced Management: MYGN's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Samraat Raha
President1yrUS$4.39m0.17%
$ 741.8k
Paul Diaz
Consultant & Director5.7yrsUS$13.63m0.66%
$ 2.8m
Paul Bisaro
Independent Director3.5yrsUS$449.35k0.043%
$ 183.9k
Lee Newcomer
Independent Director6.6yrsUS$448.00k0.088%
$ 377.1k
Daniel Skovronsky
Independent Director5.8yrsUS$433.50k0.092%
$ 393.9k
Colleen Reitan
Independent Director6.6yrsUS$443.50k0.045%
$ 194.8k
Heinrich Dreismann
Independent Director15.8yrsUS$443.50k0.13%
$ 557.1k
Mark Davis
Independent Director1.3yrsUS$350.00kno data
S. Phanstiel
Independent Chair of the Board16.6yrsUS$563.50k0.28%
$ 1.2m
Rashmi Kumar
Independent Director5.6yrsUS$433.50k0.083%
$ 354.4k
5.7yrs
Average Tenure
63.5yo
Average Age

Experienced Board: MYGN's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/14 01:59
End of Day Share Price 2026/04/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Myriad Genetics, Inc. is covered by 36 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack MeehanBarclays
Derek TallerBenchmark Company
Michael RyskinBofA Global Research